Prostate cancer is the most common cancer diagnosis in men, accounting for 30% of male cancers.

Fusion Pharmaceuticals (FUSN) is advancing a candidate which it acquired in February of 2023. It was acquired as an ongoing phase 2 study, known as the TATCIST trial. This is evaluating the use of FPI ...

JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (DRTS) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, today announced that the ...

Vancouver, British Columbia, Canada (Embargoed until 3:15 p.m. PDT, Saturday, June 11, 2022)—A novel targeted radionuclide alpha therapy for metastatic castration-resistant prostate cancer— 225 ...

Compounds containing astatine-211 (211At) can be used in targeted radiotherapies for prostate cancer, but deastatination in the body remains a significant hurdle. Now, researchers from Japan have ...

JERUSALEM, June 22, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the first ...

Osaka, Japan - A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray ...

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ...

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray therapeutic agent ...

The Red & Black is a 501c3 nonprofit. Please consider a one-time gift or become a monthly supporter. Cancel anytime. On Saturday at 9 a.m., the Athens alumni chapter of the Kappa Alpha Psi Fraternity, ...

A meta-analysis evaluated the efficacy and safety of imidafenacin for overactive bladder induced by benign prostatic hyperplasia. Combining imidafenacin with an alpha-blocker may effectively treat ...

Dublin, June 25, 2019 (GLOBE NEWSWIRE) -- The "Global Benign Prostatic Hyperplasia Market: Growth, Trends, and Forecasts (2019-2024)" report has been added to ResearchAndMarkets.com's offering. Benign ...